South Korean medical AI firm GC Medi-AI says its "Uisarang" (์์ฌ๋) AI service surpassed 1,000 prescriptions within three weeks of launch, according to a company announcement carried by Korean medical and technology outlets including Daily Medi, News1 and ET News. The milestone is the company's own count, and the announcement does not break down how much of the volume came from paying subscribers versus free-tier users โ a distinction that shapes how the figure should be read.
The 1,000-prescription mark, reached roughly three weeks after the service went live, is drawn from GC Medi-AI's official announcement rather than from an independent registry or third-party audit. Reporters reviewing the claim examined ten primary sources; because the original Daily Medi article sat behind a captcha barrier, the same wording was cross-checked directly against News1 and ET News reports, which matched the announcement's figures verbatim.
Self-reported adoption numbers of this kind are a common way for Korean digital-health startups to signal early traction, and GC Medi-AI's disclosure follows that pattern: a single aggregate figure, tied to a launch window, issued by the company that operates the service.
The key ambiguity is the composition of the count. The announcement does not specify whether the prescriptions came from clinics on paid contracts or from users on a free tier, nor does it identify the number of institutions or clinicians driving the volume. A tally dominated by free access would indicate interest in the product but say little about revenue; one concentrated among subscribed clinics would carry more commercial weight. Without that breakdown, the raw 1,000 figure is best treated as a sign of early uptake rather than a measure of monetization.
Bracketed with those caveats โ a company-compiled count of prescriptions whose paid-versus-free composition was left unstated โ the three-week milestone claim aligns with the official announcement and is Mostly True.